Bioenergetic gain of citrate anticoagulated continuous hemodiafiltration-a comparison between 2 citrate modalities and unfractionated heparin

Journal of Critical Care

Volumn 28, Issue 1, 2013, Pages 87-95

  Balik, Martin ^a   Zakharchenko, Mykhaylo ^a   Leden, Pavel ^a   Otahal, Michal ^a   Hruby, Jan ^a   Polak, Ferdinand ^a   Rusinova, Katerina ^a   Stach, Zdenek ^a   Tokarik, Monika ^b   Vavrova, Jaroslava ^c   Jabor, Antonin ^d   Oudemans van Straaten, Heleen M ^e  

^a CHARLES UNIVERSITY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^d INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^e Onze Lieve Vrouwe Gasthuis ^*  (Netherlands)

Author keywords

Acute renal failure; Anticoagulation; Citrate; Hemodiafiltration; Renal replacement therapy

Indexed keywords

BICARBONATE; CALCIUM; CITRATE TRISODIUM; CITRIC ACID; GLUCOSE; HEPARIN; LACTIC ACID;

ADULT; ARTICLE; BIOENERGY; BLOOD FLOW; CITRATE ANTICOAGULATED CONTINUOUS HEMODIAFILTRATION; COMPARATIVE STUDY; CONTINUOUS HEMODIAFILTRATION; CONTROLLED STUDY; DIALYSATE; FEMALE; HUMAN; INTENSIVE CARE UNIT; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; OBSERVATIONAL STUDY; PROSPECTIVE STUDY;

ACUTE KIDNEY INJURY; ANTICOAGULANTS; CITRATES; DIALYSIS SOLUTIONS; ENERGY INTAKE; ENERGY METABOLISM; FEMALE; HEALTH CARE COSTS; HEMODIAFILTRATION; HEPARIN; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; WATER-ELECTROLYTE IMBALANCE;

EID: 84870810150     PISSN: 08839441     EISSN: 15578615     Source Type: Journal    
DOI: 10.1016/j.jcrc.2012.06.003     Document Type: Article

References (29)

1. Oudemans-van Straaten H.M., Wester J.P., de Pont A.C., et al. Anticoagulation strategies in continuous renal replacement therapy: can the choice be evidence based?. Intensive Care Med 2006, 32:188-202.
2. Monchi M., Berghmans D., Ledoux D., et al. Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study. Intensive Care Med 2005, 30:260-265.
3. Zhang Z., Hongying N. Efficacy and safety of regional citrate anticoagulation in critically ill patients undergoing continuous renal replacement therapy. Intensive Care Med 2012, 38:20-28. 10.1007/s00134-011-2438-3.
4. Oudemans-van Straaten H.M., Bosman R.J., Koopmans M., et al. Citrate anticoagulation for continuous venovenous hemofiltration. Crit Care Med 2009, 37:545-552.
5. Hetzel G.R., Schmitz M., Wissing H., et al. Regional citrate versus systemic heparin for anticoagulation in critically ill patients on continuous venovenous haemofiltration: a prospective randomized multicentre trial. Nephrol Dial Transplant 2011, 26:232-239.
6. Kutsogiannis D.J., Gibney R.T., Stollery D., et al. Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients. Kidney Int 2005, 67:2361-2367.
7. Bagshaw S.M., Laupland K.B., Boiteau P.J., et al. Is regional citrate superior to systemic heparin anticoagulation for continuous renal replacement therapy? A prospective observational study in an adult regional critical care system. J Crit Care 2005, 20:155-161.
8. Balik M., Waldauf P., Plasil P., et al. Prostacyclin versus citrate in continuous haemodiafiltration: an observational study in patients with high risk of bleeding. Blood Purif 2005, 23:325-329.
9. Morgera S., Scholle C., Voss G., et al. Metabolic complications during regional citrate anticoagulation in continuous venovenous hemodialysis: single-center experience. Nephron Clin Pract 2004, 97:131-136.
10. Morgera S., Schneider M., Slowinski T., et al. A safe citrate anticoagulation protocol with variable treatment efficacy and excellent control of the acid-base status. Crit Care Med 2009, 37:2018-2024.
11. Mariano F., Morselli M., Bergamo D., et al. Blood and ultrafiltrate dosage of citrate as a useful and routine tool during continuous venovenous haemodiafiltration in septic shock patients. Nephrol Dial Transplant 2011, 26:3882-3888.
12. van Straaten HM Oudemans, Bellomo R., Kellum J.A. Anticoagulation for continuous renal replacement therapy-heparin or citrate?. Crit Care 2011, 15:202.
13. Swartz R., Pasko D., O'Toole J., et al. Improving the delivery of continuous renal replacement therapy using regional citrate anticoagulation. Clin Nephrol 2004, 61:134-143.
14. Chadha V., Garg U., Warady B.A., et al. Citrate clearance in children receiving continuous venovenous renal replacement therapy. Pediatr Nephrol 2002, 17:819-824.
15. Mariano F., Tedeschi L., Morselli M., et al. Normal citratemia and metabolic tolerance of citrate anticoagulation for hemodiafiltration in severe septic shock burn patients. Intensive Care Med 2010, 36:1735-1743.
16. Gupta M., Wadhwa N.K., Bukovski R. Regional citrate anticoagulation for continuous venovenous hemodiafiltration using calcium-containing dialysate. Am J Kidney Dis 2004, 43:67-73.
17. Palsson R., Niles J.L. Regional citrate anticoagulation in continuous venovenous hemofiltration in critically ill patients with a high risk of bleeding. Kidney Int 1999, 55:1991-1997.
18. Balik M., Zakharchenko M., Otahal M., et al. Quantification of systemic dose of substrates for intermediate metabolism during citrate anticoagulation of continuous renal replacement therapy. Blood Purif 2012, 33:80-87.
19. Bellomo R., Cass A., Cole L., et al. Intensity of continuous renal-replacement therapy in critically ill patients. N Engl J Med 2009, 361:1627-1638. RENAL Replacement Therapy Study Investigators.
20. VA/NIH Acute Renal Failure Trial Network, Palevsky P.M., Zhang J.H., O'Connor T.Z. Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med 2008, 359:7-20.
21. Relton S., Greenberg A., Palevsky P.M. Dialysate and blood flow dependence of diffusive solute clearance during CVVHD. ASAIO J 1992, 38:691-696.
22. Marino P.L., Sutin K.M. Hemodynamic monitoring. The ICU book 2007, 194-208. Lippincot, Williams and Wilkins, Philadelphia. 3rd ed. P.L. Marino, K.M. Sutin (Eds.).
23. Hetzel G.R., Taskaya G., Sucker C., et al. Citrate plasma levels in patients under regional anticoagulation in continuous venovenous hemofiltration. Am J Kidney Dis 2006, 48:806-811.
24. Bollmann M.D., Revelly J.P., Tappy L., et al. Effect of bicarbonate and lactate buffer on glucose and lactate metabolism during haemodiafiltration in patients with multiple organ failure. Intensive Care Med 2004, 30:1103-1110.
25. Levy B., Mansart A., Montemont C., et al. Myocardial lactate deprivation is associated with decreased cardiovascular performance, decreased myocardial energetics, and early death in endotoxic shock. Intensive Care Med 2007, 33:495-502.
26. Leverve X., Mustafa I., Novak I., et al. Lactate metabolism in acute uremia. J Ren Nutr 2005, 15:58-62.
27. Balik M., Waldauf P., Glocknerova K., Kusova D. Lactate buffered dialysis in cardiogenic shock associated with severe combined lactic acidosis. Nephrol Dial Transplant Plus 2008, 1:103-105.
28. Uchino S., Fealy N., Baldwin I., et al. Continuous is not continuous: the incidence and impact of circuit "down-time" on uraemic control during continuous veno-venous haemofiltration. Intensive Care Med 2003, 29:575-578.
29. Brunet S., Leblanc M., Geadah D., et al. Diffusive and convective solute clearances during continuous renal replacement therapy at various dialysate and ultrafiltration flow rates. Am J Kidney Dis 1999, 34:486-492.